Please don’t bury the lede

The next set of value assessments by the Institute for Clinical and Economic Review could better reflect patient input and the benefits new therapies provide while providing more context for budget setting by payers. But the jury will remain out until stakeholders are convinced the transformations clearly and prominently communicate the assumptions and variables underlying ICER’s determinations of value.

The first test will come in April when the ICER releases its draft assessment of osteoporosis drugs...